Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer.
OBJECTIVE: ¹⁸F-fluorodeoxyglucose positron emission tomography (FDG PET) has been shown to improve the accuracy of staging in oesophageal cancer. We assessed the benefit of PET/CT over conventional staging and determined if tumour histology had any significant impact on PET/CT findings. METHODS: A...
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Journal article |
| Jazyk: | English |
| Vydáno: |
2011
|
| _version_ | 1826302090827268096 |
|---|---|
| author | Gillies, R Middleton, MR Maynard, N Bradley, K Gleeson, F |
| author_facet | Gillies, R Middleton, MR Maynard, N Bradley, K Gleeson, F |
| author_sort | Gillies, R |
| collection | OXFORD |
| description | OBJECTIVE: ¹⁸F-fluorodeoxyglucose positron emission tomography (FDG PET) has been shown to improve the accuracy of staging in oesophageal cancer. We assessed the benefit of PET/CT over conventional staging and determined if tumour histology had any significant impact on PET/CT findings. METHODS: A retrospective cohort study, reviewing the results from 200 consecutive patients considered suitable for radical treatment, undergoing routine PET/CT staging comparing the results from CT and endoscopic ultrasound, as well as multi-disciplinary team records. Adenocarcinoma and squamous cell carcinoma were compared for maximum Standardised Uptake Value (SUV(max)), involvement of local lymph nodes and distant metastases. RESULTS: PET/CT provided additional information in 37 patients (18.5%) and directly altered management in 34 (17%): 22 (11%) were upstaged; 15 (7.5%) were downstaged, 12 of whom (6%) received radical treatment. There were 11 false negatives (5.5%) and 1 false positive (0.5%). SUV(max) was significantly lower for adenocarcinoma than squamous cell carcinoma (median 9.1 versus 13.5, p = 0.003). CONCLUSIONS: Staging with PET/CT offers additional benefit over conventional imaging and should form part of routine staging for oesophageal cancer. Adenocarcinoma and squamous cell carcinoma display significantly different FDG-avidity. |
| first_indexed | 2024-03-07T05:42:15Z |
| format | Journal article |
| id | oxford-uuid:e5f9524d-e8d2-4759-9ff6-fd2c11b8f8bd |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:42:15Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:e5f9524d-e8d2-4759-9ff6-fd2c11b8f8bd2022-03-27T10:27:55ZAdditional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:e5f9524d-e8d2-4759-9ff6-fd2c11b8f8bdEnglishSymplectic Elements at Oxford2011Gillies, RMiddleton, MRMaynard, NBradley, KGleeson, F OBJECTIVE: ¹⁸F-fluorodeoxyglucose positron emission tomography (FDG PET) has been shown to improve the accuracy of staging in oesophageal cancer. We assessed the benefit of PET/CT over conventional staging and determined if tumour histology had any significant impact on PET/CT findings. METHODS: A retrospective cohort study, reviewing the results from 200 consecutive patients considered suitable for radical treatment, undergoing routine PET/CT staging comparing the results from CT and endoscopic ultrasound, as well as multi-disciplinary team records. Adenocarcinoma and squamous cell carcinoma were compared for maximum Standardised Uptake Value (SUV(max)), involvement of local lymph nodes and distant metastases. RESULTS: PET/CT provided additional information in 37 patients (18.5%) and directly altered management in 34 (17%): 22 (11%) were upstaged; 15 (7.5%) were downstaged, 12 of whom (6%) received radical treatment. There were 11 false negatives (5.5%) and 1 false positive (0.5%). SUV(max) was significantly lower for adenocarcinoma than squamous cell carcinoma (median 9.1 versus 13.5, p = 0.003). CONCLUSIONS: Staging with PET/CT offers additional benefit over conventional imaging and should form part of routine staging for oesophageal cancer. Adenocarcinoma and squamous cell carcinoma display significantly different FDG-avidity. |
| spellingShingle | Gillies, R Middleton, MR Maynard, N Bradley, K Gleeson, F Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer. |
| title | Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer. |
| title_full | Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer. |
| title_fullStr | Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer. |
| title_full_unstemmed | Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer. |
| title_short | Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer. |
| title_sort | additional benefit of ¹⁸f fluorodeoxyglucose integrated positron emission tomography computed tomography in the staging of oesophageal cancer |
| work_keys_str_mv | AT gilliesr additionalbenefitof18ffluorodeoxyglucoseintegratedpositronemissiontomographycomputedtomographyinthestagingofoesophagealcancer AT middletonmr additionalbenefitof18ffluorodeoxyglucoseintegratedpositronemissiontomographycomputedtomographyinthestagingofoesophagealcancer AT maynardn additionalbenefitof18ffluorodeoxyglucoseintegratedpositronemissiontomographycomputedtomographyinthestagingofoesophagealcancer AT bradleyk additionalbenefitof18ffluorodeoxyglucoseintegratedpositronemissiontomographycomputedtomographyinthestagingofoesophagealcancer AT gleesonf additionalbenefitof18ffluorodeoxyglucoseintegratedpositronemissiontomographycomputedtomographyinthestagingofoesophagealcancer |